

## CURRICULUM VITAE

### **Roman Shrestha, PhD, MPH**

---

University of Connecticut  
College of Agriculture, Health, and Natural Resources  
Department of Allied Health Sciences  
358 Mansfield Rd. U-1101  
Storrs, CT 06269  
e-mail: [roman.shrestha@uconn.edu](mailto:roman.shrestha@uconn.edu)

---

#### **EDUCATION AND TRAINING**

- 2018-2019    **Postdoctoral Fellow**  
AIDS Program, Yale University
- 2017-2018    **Postdoctoral Research Associate**  
Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut
- 2013-2017    **PhD, Public Health**  
Department of Public Health Sciences, University of Connecticut  
Dissertation: “*Developing and testing an integrated, brief bio-behavioral HIV prevention intervention targeting high-risk drugs users in treatment*”
- Awarded the ‘**Outstanding Dissertation Award 2018**’ and the ‘**Optimization of Behavioral & Biobehavioral Interventions Research Award**’ by the Society of Behavioral Medicine
- 2011-2013    **MPH, Public Health**  
University of Connecticut  
Thesis: “*Understanding HIV risk behaviors among migrant workers in Nepal*”
- 2007-2011    **BS, Biology (*Summa cum laude*)**  
Wiley College

#### **ACADEMIC AND RESEARCH APPOINTMENTS**

- 2021-        **Assistant Professor**  
Allied Health Sciences, University of Connecticut
- 2021-        **Principal Investigator**  
Institute for Collaboration on Health, Intervention, & Policy, University of Connecticut
- 2019-        **Visiting Senior Lecturer**  
Centre of Excellence for Research in AIDS (CERiA), University of Malaya
- 2019-2020    **Associate Research Scientist (Faculty)**  
AIDS Program, Department of Internal Medicine, Yale School of Medicine

2018-	<b>Research Affiliate</b> Center for Interdisciplinary Research on AIDS, Yale University
2015-2017	<b>Teaching Assistant</b> Department of Allied Health Sciences, University of Connecticut
2015-2016	<b>Instructor</b> Department of Allied Health Sciences, University of Connecticut
2012-2018	<b>Research Assistant</b> University of Connecticut Project: <i>Secondary HIV Prevention and Adherence Among HIV-infected Drug Users</i> (National Institute on Drug Abuse; R01DA032290, PI Copenhagen)
2011-2012	<b>Research Assistant</b> University of Connecticut Project: <i>Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users</i> (National Institute on Drug Abuse; R01DA022122, PI Copenhagen)
2009-2011	<b>Research Intern</b> CT-RI Public Health Training Center Program, UConn Health Center
2009-2011	<b>Academic Tutor</b> Student Support Services, Wiley College

## **GRANTS**

### ***Ongoing***

2020-2025	<b>Principal Investigator</b> <i>Training in mHealth Prevention with MSM</i> National Institute on Drug Abuse, K01DA051346	\$765,496
2020-2025	<b>Principal Investigator</b> <i>Development and testing of a mobile app to enhance HIV prevention cascade in Malaysian MSM</i> Fogarty International Center, R21TW011665 (R21/R33)	\$1,319,241
2020-2022	<b>Principal Investigator</b> <i>Integrated rapid access to HIV prevention program for people who inject drugs (iRaPID)</i> National Institute on Drug Abuse, R21DA051934	\$460,625
2019-2021	<b>Principal Investigator</b> <i>Expanding Pre-Exposure Prophylaxis (PrEP) Implementation in Communities of People Who Inject Drugs and Their Risk Network Members</i>	\$522,126

Gilead Investigator Sponsored Research, IN-US-412-5629

2019-2021	<b>Co-Investigator (PI Yale Subaward)</b> <i>Examining Ethical Concerns in the Context of App-Based HIV Prevention Research with Men who have Sex with Men in the Malaysian Context</i> National Institute on Drug Abuse, R25DA031608 (PI Fisher)	\$25,000
2018-2021	<b>Co-Investigator (PI Yale Subaward)</b> <i>Methadone vs. Buprenorphine Therapy for Opioid Dependence: Diet and Metabolic Implications</i> Rutgers University Busch Biomedical Grant Program (PI Rawal)	\$39,935

***Funding Under Consideration (JIT Submitted)***

2020-2022	<b>Principal Investigator (Wickersham, MPI)</b> <i>Improving HIV testing and PrEP for transgender women through mHealth</i> National Institute of Allergy and Infectious Diseases, R21[Score: 26]	\$460,625
-----------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------

***Under Review***

2020-2025	<b>Consultant</b> <i>Targeting HIV prevention using mHealth for transgender women in Malaysia</i> Fogarty International Center, R21/R33 (PI Wickersham)	\$1,370,675
2020-2025	<b>Consultant</b> <i>Development and testing of an app-based smoking cessation intervention for people living with HIV</i> National Institute on Drug Abuse, R21/R33 (PI Poudel)	\$1,460,332
2021-2022	<b>Consultant</b> <i>Strengthening the HIV care continuum for transgender women living with HIV in Malaysia</i> National Institute of Mental Health, R21 (PI Wickersham)	\$691,619

***Completed***

2018-2020	<b>Principal Investigator</b> <i>Theory-based approach to pre-exposure prophylaxis (PrEP) uptake among men who have sex with men (MSM) in Malaysia</i> Yale Lesbian, Gay, Bisexual, and Transgender Studies	\$5,000
2016-2018	<b>Principal Investigator</b> <i>Integrated bio-behavioral HIV prevention intervention targeting PWID</i> Institute for Collaboration on Health, Intervention, & Policy (InCHIP) Seed Grant, University of Connecticut	\$2,000
2014-2016	<b>Principal Investigator</b>	\$2,000

*Developing an evidence-based intervention targeting high-risk migrant workers*  
 Institute for Collaboration on Health, Intervention, & Policy (InCHIP) Seed  
 Grant, University of Connecticut

2011-2013 **Principal Investigator** \$1,500  
*HIV-related risk behaviors among returnee male migrant workers in Nepal*  
 College on Liberal Arts and Sciences (CLAS) Research Grant, University of  
 Connecticut

### ***Unfunded***

2020-2025 **Co-Investigator** (Subaward) \$460,332  
*Developing optimal primary HIV prevention among non-treatment seeking  
 opioid-dependent persons*  
 National Institute on Drug Abuse, R01 (PI Copenhaver)

### **FELLOWSHIPS, HONORS, AND ACADEMIC RECOGNITION**

2020 **Travel Award**, 12<sup>th</sup> International Women's and Children's Health and Gender  
 (InWomen's) Group

2019 **Fellow, Fordham HIV and Drug Prevention Research Ethics Training  
 Institute**, Funded by the National Institute on Drug Abuse (NIDA)

2019 **Fellow, Training on Optimization of Behavioral & Biobehavioral  
 Interventions**, Funded by the Office of Behavioral & Social Science Research  
 (OBSSR)/NIDA

2019 **Travel Award**, 11<sup>th</sup> International Women's and Children's Health and Gender  
 (InWomen's) Group

2018 **International Conference on Stigma Scholarship**, Howard University

2018 **Ending Gender Inequalities Conference Travel Award**, RTI International

2018 **Alumni Inductee**, Delta Omega National Public Health Honor Society

2018 **Outstanding Dissertation Award**, Society of Behavioral Medicine (SBM)

2018 **Optimization of Behavioral & Biobehavioral Interventions Research Award**,  
 Society of Behavioral Medicine (SBM)

2017 **Top Reviewer in Medicine – 2017**, Publons Peer Review Awards 2017

2016 **COMPACT for Faculty Diversity Travel Award**, Graduate School (University of  
 Connecticut)

2016 **Travel Award for Early Career Investigators**, College on Problems of Drug  
 Dependence (CPDD)

2016 **Ending Gender Inequalities Conference Travel Award**, RTI International

2015 **NIDA Women and Sex/Gender Differences Junior Investigator Travel Award**,  
 National Institute on Drug Abuse

2015 **Doctoral Student Travel Award**, Graduate School (University of Connecticut)

2011-2012 **Predocorial Fellowship**, University of Connecticut

2007-2011 **Presidential Scholarship**, Wiley College

2011 **Allen Mercer Mayes & Laverne Hadnott Mayes Endowed Scholarship**,  
 University of Rhode Island

- 2010 **Destination Public Health Travel Award**, Rollins School of Public Health (Emory University)
- 2010 **Who's Who Among Students in American Universities & Colleges**, USA
- 2007 **International Student Award**, Wiley College
- 2004-2005 **Mahatma Gandhi Scholarship**, Indian Embassy, Nepal
- 2004 **Presidential Scholarship**, Ambition Academy, Nepal

## **PROFESSIONAL SERVICES**

### **Grant Reviewing**

- 2020 **Centers for Disease Control and Prevention** for *Special Emphasis Panel Review: PS21-001*
- 2020 **Centers for Disease Control and Prevention** for *Special Emphasis Panel Review: PS20-001*
- 2017 **National Science Centre Reviewer** (Poland) for *SONATA (Early career award)*
- 2015 **Institute for Collaboration on Health, Intervention, and Policy**, *Graduate Student Seed Grant reviewer*

### **Journal Service**

- 2018-Current **Consulting Editor** for *AIDS & Behavior*
- 2020-Current **Associate Editor** for *Contemporary Clinical Trials*
- 2017-Current **Associate Editor** for *BMC Women's Health*
- 2017-2019 **Associate Editor** for *BMC Public Health*
- 2015-Current **Reviewer** for *Journal of the International AIDS Society; American Journal of Public Health; and Alcohol Dependence; Journal of Acquired Immune Deficiency Syndromes; Addictive Behaviors; AIDS & Behavior; BMJ Open; AIDS Care; Clinical Epidemiology; Medicine; Contemporary Clinical Trials; Journal of Substance Abuse Treatment; International Journal of STD & AIDS; BMC Public Health; Journal of the International Association of Providers of AIDS Care; Frontiers in Public Health; Health and Quality of Life Outcomes; Journal of Medical Internet Research; LGBT Health; International Social Work; Patient Preference and Adherence; Journal of Immigrant and Minority Health; Substance Abuse: Research & Treatment; PLoS ONE; JMIR mHealth and uHealth; BMC Women's Health; Journal of HIV/AIDS & Social Services; Substance Abuse and Rehabilitation; HIV/AIDS - Research and Palliative Care; Tobacco Use Insights*

### **Professional Organizations**

- 2016-Present Member, International AIDS Society (IAS)
- 2015-Present Member, Society for Behavioral Medicine (SBM)
- 2012-Present Member, American Public Health Association (APHA)
- 2012-2017 Member, Connecticut Public Health Association (CPHA)
- 2012-2017 Member, Public Health Student Organization (PHSO), UConn Health Center

### **Additional Services**

- 2020 **AIDS 2020 International Scholarship Application Reviewer Committee**, International AIDS Society (IAS)

- 2019 **2019 Multiple Health Behavior Change SIG Student Award Search Committee**, Society for Behavioral Medicine (SBM)
- 2018 **Outstanding Trainee Abstract in Health Decision Making Search Committee**, Society for Behavioral Medicine (SBM)
- 2018-2020 **IAS Conference – Abstract Mentor**, International AIDS Society (IAS)
- 2017 **Co-Liaison**, Violence & Trauma Special Interest Group, Society of Behavioral Medicine (SBM)
- 2017 **Oral Session Moderator**, 2017 American Public Health Association Annual Conference
  - HIV and Substance Use
  - HIV Prevention in Injection Drug Users
- 2011-2012 **Website Committee Chair**, Student Assembly, American Public Health Association (APHA)

## **PUBLICATIONS**

(\*denotes current/former undergraduate or graduate student)

### **Book Chapters**

1. **Shrestha, R.**, Benjamin, M.\*, & Meyer, J. (2020). Pre-Exposure Prophylaxis (PrEP) for People Who Inject Drugs (PWID). In *‘The Opioid Epidemic and Infectious Diseases* (pp. 223-236). Elsevier. doi: 10.1016/B978-0-323-68328-9.00011-4
2. **Shrestha, R.**, Karki, P.\*, & Copenhaver, M. (2019). Addressing the Challenges of Neuro-cognitive Impairment (NCI) on Treatment Engagement. In *‘The Wiley Handbook of Patient Engagement in Healthcare Treatment: Theory, Research and Clinical Practice* (pp. 109-140). Wiley. doi: 10.1002/9781119129530.ch6

### **Peer-Reviewed Publications (Accepted)**

1. **Shrestha, R.**, DiDomizio, L.\*, Kim, R.\*, Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. *Journal of Substance Use Treatment*. (In press). doi: 10.1016/j.jsat.2020.108058
2. **Shrestha, R.**, Alias, H., Wong, L. P., Altice, F., & Lim, H. (2020). Using individual stated-preferences to optimize HIV self-testing service delivery among men who have sex with men (MSM) in Malaysia: Results from a conjoint-based analysis. *BMC Public Health*, 20 (1777). doi: 10.1186/s12889-020-09832-w
3. Ni, Z.\*, Altice, F., Copenhaver, M., DiDomizio, L.\*, Wickersham, J., & **Shrestha, R.** (2020). Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. *Drug and Alcohol Dependence*. (In press).
4. Mistler, C.\*, Copenhaver, M., & **Shrestha, R.** (2020). The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs (PWID): A systematic review. *AIDS & Behavior*. (In press). doi: 10.1007/s10461-020-02988-x

5. **Shrestha, R.**, Galka, J.M., Azwa, I., Lim, H., Guadamuz, T. E., Altice, F., & Wickersham, J. (2020). Willingness to Use HIV Self-Testing and Associated Factors among Transgender Women in Malaysia. *Transgender Health*. (In press). doi: 10.1089/trgh.2019.0085
6. Ni, Z.\*, Lebowitz, E.R., Zou, Z., Wang, H., Liu, H., Hu, J., Wu, J., Zhang, L., **Shrestha, R.**, & Altice, F. (2020). Response to the COVID-19 Outbreak in Urban Settings in China. *Journal of Urban Health*. (In press). doi: 10.1007/s11524-020-00498-8
7. Copenhaver, M., Sanborn, V., **Shrestha, R.**, Mistler, C.\*, & Gunstad, J. (2020). Validation of the Brief Inventory of Neurocognitive Impairment (BINI) among opioid-dependent persons in drug treatment: Efficient screening that can drive tailored treatment. *Journal of Psychoactive Diseases*. doi: 10.1080/10550887.2020.1831129
8. Mistler, C.\*, Chandra, D., Copenhaver, M., Wickersham, J., & **Shrestha, R.** (2020). Engagement in harm reduction strategies after suspected fentanyl contamination among opioid-dependent individuals. *Journal of Community Health*. (In press).
9. **Shrestha, R.**, Altice, F., DiDomizio, L.\*, Sibilio, B., Ranjit, Y., & Copenhaver, M. (2020). Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis. *Patient Preference and Adherence*, 14: 107-118. doi: 10.2147/PPA.S236794
10. Sanborn, V., Gunstad, J., **Shrestha, R.**, Mistler, C.\*, & Copenhaver, M. (2020). Cognitive profiles in persons with opioid use disorder enrolled in methadone treatment. *Applied Neuropsychology: Adult*. (In press). doi: 10.1080/23279095.2020.1769099
11. Ranjit, Y.S., **Shrestha, R.**, Copenhaver, M., Altice, F.L. (2020). Online HIV Information Seeking and Pre-Exposure Prophylaxis Awareness among People Who Use Drugs. *Journal of Substance Abuse Treatment*, 111: 16-22. doi: 10.1016/j.jsat.2019.12.010
12. Galka, J., Wang, M., Azwa, I., Gibson, B., Lim, H., **Shrestha, R.**, & Wickersham, J. (2020). Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV Prevention and PrEP Implementation Preferences Among Transgender Women in Malaysia. *Transgender Health*. (In press). doi: 10.1089/trgh.2020.0003
13. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). HIV-Related Stigma, Motivation for Medication Adherence, Viral Suppression, and Adherence to Antiretroviral Therapy (ART) among HIV-Positive Drug Users. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 80(2):166-173. doi: 10.1097/QAI.0000000000001891
14. **Shrestha, R.**, Lim, H.S., Altice, F. L., Copenhaver, M.M., Wickersham, J., Saifi, R., Halim, M.A., Naning, H., & Kamarulzaman, A. (2019). Use of Smartphone to Seek Sexual Health Information Online Among Malaysian Men Who Have Sex with Men (MSM): Implications for mHealth Intervention to increase HIV testing and reduce HIV risks. *Journal of Community Health*. doi: 10.1007/s10900-019-00713-x

15. **Shrestha, R.**, Altice, F., Sibilio, B., Ssenyonjo, J.\*, & Copenhaver, M. (2019). Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. *Contemporary Clinical Trials*, 82: 77-84. doi: 10.1016/j.cct.2019.06.012
16. Ssenyonjo, J.\*, **Shrestha, R.**, & Copenhaver, M. (2019). Influence of Stigma on Pre-Exposure Prophylaxis (PrEP) Care Continuum Among Men and Transwomen Who Have Sex with Men (MTWSM) in the United States. *International Journal of HIV/AIDS Prevention, Education, and Behavioural Science*. 5: 134-140. doi: 10.11648/j.ijhpebs.20190502.18
17. **Shrestha, R.** & Copenhaver, M. (2018). Viral Suppression among HIV-Infected Methadone-Maintained Patients: The Role of Ongoing Injection Drug Use and Adherence to Antiretroviral Therapy (ART). *Addictive Behaviors*, 85:88-93. doi: 10.1016/j.addbeh.2018.05.031
18. **Shrestha, R.**, Altice, F., Karki, P.\*, & Copenhaver, M. M. (2018). Integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs: A pilot feasibility study. *AIDS & Behavior*, 22(8):2640-2649. doi: 10.1007/s10461-018-2099-0
19. **Shrestha, R.**, Altice, F., Sibilio, B., & Copenhaver, M. (2018). HIV Sero-Status Non-Disclosure among High-Risk Drug Users Living with HIV: The Roles of HIV-Related Stigma, Risk Behavior, and Social Support. *Journal of Community Health*, 44(1):112-120. doi: 10.1007/s10900-018-0560-7
20. **Shrestha, R.**, & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Drug Users. *Frontiers in Public Health*, 6:195 doi: 10.3389/fpubh.2018.00195
21. **Shrestha, R.**, Karki, P., Altice, F., Dubov, O., Fraenkel, L., Huedo-Medina, T., & Copenhaver, M. M. (2017). Measuring Acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: An application to primary HIV prevention among high-risk drug users. *AIDS & Behavior*, 22(4):1228-1238. doi: 10.1007/s10461-017-1851-1
22. **Shrestha, R.**, Altice, F., Karki, P., & Copenhaver, M. (2017). Developing a Bio-Behavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: Taking into Account the Impact of Neurocognitive Impairment. *Frontiers in Immunology*, 8:561. doi: 10.3389/fimmu.2017.00561
23. **Shrestha, R.**, Karki, P., Huedo-Medina, T., Altice, F., Meyer, J., Madden, L., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis and the likelihood of practicing safer drug- and sex-related risk behaviors among high-risk

- drug users in treatment. *Drug and Alcohol Dependence*, 173:107-116. doi: 10.1016/j.drugalcdep.2016.12.023
24. Bazazi, A.R., Wickersham, J., Wegman, M., Pillai, V., Culbert, G., **Shrestha, R.**, Al-Darraj, H., Copenhaver, M., Kamarulzaman, A., & Altice, F.L. (2017). Design and implementation of a factorial randomized controlled trial of methadone maintenance therapy and an evidence-based behavioral intervention for incarcerated people living with HIV and opioid dependence in Malaysia. *Contemporary Clinical Trials*, 59:1-12. doi: 10.1016/j.cct.2017.05.006
  25. **Shrestha, R.**, Karki, P., & Copenhaver, M. M. (2017). Interest in Use of mHealth Technology in HIV Prevention and Associated Factors among High-Risk Drug Users in Treatment. *AIDS Care*, 29(9):1144-1148. doi: 10.1080/09540121.2017.1325439
  26. **Shrestha, R.**, Weikum, D., Copenhaver, M., & Altice, F. (2017). A Self-report Measure to Detect Neurocognitive Impairment Among Incarcerated People Living with HIV in the Malaysian Context: an Exploratory Factor Analysis. *International Journal of Mental Health and Addiction*, 15(4):812-825. doi: 10.1007/s11469-017-9752-0
  27. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. M. (2017). Intent to use pre-exposure prophylaxis (PrEP), HIV risk behaviors, and self-report neurocognitive symptoms among high-risk drug users: A mediation analysis. *Journal of the Association of Nurses in AIDS Care*, 28(4):612-621. doi: 10.1016/j.jana.2017.04.005
  28. Weikum, D., **Shrestha, R.**, Ferro, E.G., Vagenas, P., Copenhaver, M., Spudich, S., Alpert, M.D., Cabello, R., Lama, J.R., Sanchez, J., & Altice, F. (2017). An Explanatory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among HIV-infected Men Who Have Sex with Men and Transgender Women in Peru. *AIDS Care*, 29(10):1297-1301. doi: 10.1080/09540121.2017.1322681
  29. **Shrestha, R.**, Huedo-Medina, T., Krishnan, A., Altice, F., & Copenhaver, M. (2016). Examining the Acceptability of mHealth Technology in HIV Prevention among High-risk Drug Users in Treatment. *AIDS and Behavior*, 21(11): 3100-3110. doi: 10.1007/s10461-016-1637-x
  30. **Shrestha, R.**, Copenhaver, M., Krishnan, A., Bazazi, A., & Altice, F. (2016). A Moderated Mediation Model of HIV-Related Stigma, Depression, and Social Support on Quality of Life among Incarcerated HIV-Positive Malaysian Men with Opioid Dependence. *AIDS and Behavior*, 21(4): 1059-1069. doi: 10.1007/s10461-017-1693-x
  31. **Shrestha, R.**, Huedo-Medina, T. B., Altice, F., Karki, P., & Copenhaver, M. M. (2016). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. *AIDS and Behavior*, 21(5):1299-1308. doi: 10.1007/s10461-016-1650-0

32. **Shrestha, R.**, Weikum, D., Copenhaver, M., & Altice, F. (2016). The Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Quality of Life among Incarcerated, HIV-Positive Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. *AIDS & Behavior*, 21(4):1070-1081. doi: 10.1007/s10461-016-1526-3.
33. **Shrestha, R.**, Karki, P., Huedo-Medina, T., & Copenhaver, M. (2016). Treatment engagement moderates the effect of neurocognitive impairment on antiretroviral therapy adherence among HIV-infected drug users in treatment. *Journal of the Association of Nurses in AIDS Care*, 28(1):85-94. doi: dx.doi.org/10.1016/j.jana.2016.09.007
34. Huedo-Medina, T. B., **Shrestha, R.**, & Copenhaver, M. M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users in Treatment. *AIDS & Behavior*, 20(8):1646-57. doi: 10.1007/s10461-016-1394-x
35. Copenhaver, M., **Shrestha, R.**, Wickersham, J. A., Weikum, D., & Altice, F. L. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. *Journal of Substance Abuse Treatment*, 63:61-65. doi: 10.1016/j.jsat.2016.01.002
36. **Shrestha, R.**, & Copenhaver, M. (2016). The Influence of Neurocognitive Impairment on HIV Risk Behaviors among High-Risk Drug Users: A Systematic Review. *Frontiers in Public Health*, 4:16. doi: 10.3389/fpubh.2016.00016
37. Karki, P., **Shrestha, R.**, Huedo-Medina, T., & Copenhaver, M. (2016). The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: A systematic review. *Evidence-based Medicine and Public Health*, 2(e1229):1-6. doi: 10.14800/emph.1229
38. **Shrestha, R.**, Karki, P., & Copenhaver, M. (2016). Use of Commercial Sex Workers among Men in Nepal: Prevalence, STIs/HIV-related Risk Behaviors, and Gender Ideology. *Primary Prevention Insights*, 6:11-17. doi: <http://dx.doi.org/10.4137/PPRI.S39664>
39. **Shrestha, R.**, & Copenhaver, M. (2016). Association between Intimate Partner Violence against Women and HIV Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Violence Against Women*. 22(13):1621-1641. doi: 10.1177/1077801216628690
40. **Shrestha, R.**, Karki, P., Pandey, S., & Copenhaver, M. (2016). Adapting an Evidence-Based HIV Prevention Intervention Targeting High-Risk Migrant Workers: The Process and Outcome of Formative Research. *Frontiers in Public Health*, 4:61. doi: 10.3389/fpubh.2016.00061
41. **Shrestha, R.**, Huedo-Medina, T. B., & Copenhaver, M. M. (2015). Sex-Related Differences in Self-Reported Neurocognitive Impairment among High-Risk Cocaine

- Users in Methadone Maintenance Treatment Program. *Substance Abuse: Research and Treatment*, 9:17-24. doi: 10.4137/SART.S23332
42. **Shrestha, R.**, Krishnan, A., Altice, F., & Copenhaver, M. (2015). A Non-Inferiority Trial of an Evidence-Based Secondary HIV Prevention Behavioral Intervention Compared to an Adapted, Abbreviated Version: Rationale and Intervention Description. *Contemporary Clinical Trials*, 44:95-102. doi: 10.1016/j.cct.2015.08.002
  43. **Shrestha, R.**, Karki, P., & Copenhaver, M. (2015). Early sexual debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. *Journal of Community Health*, 41(1):70-77. doi: 10.1007/s10900-015-0065-6
  44. **Shrestha, R.**, & Copenhaver, M. (2015). Long-Term Effects of Childhood Risk Factors on Cardiovascular Health during Adulthood. *Clinical Medicine Reviews in Vascular Health*, 7:1-5. 10.4137/CMRVH.S29964.
  45. **Shrestha, R.**, Karki, P., Suwal, A. & Copenhaver, M. (2015). Sex Trafficking Related Knowledge, Awareness, and Attitudes Among Adolescent Female Students in Nepal: A Cross-Sectional Study. *PLoS ONE*, 10(7): e0133508. doi: 10.1371/journal.pone.0133508
  46. Baldwin, P., **Shrestha, R.**, Potrepka, J., & Copenhaver, M. (2013). The Age of Initiation of Drug Use and Sexual Behavior May Influence Subsequent HIV Risk Behavior: A Systematic Review. *ISRN AIDS*, 2013:976035. doi: 10.1155/2013/976035
  47. **Shrestha, R.** (2012). Maternal Mortality in Nepal: Addressing the Issue. *International Journal of Health Sciences Research*, 2(9):65-74.
  48. **Shrestha, R.** (2012). Arsenic Contamination of Groundwater in Nepal: Good Public Health Intention Gone Bad. *Inquiries Journal/Student Pulse*, 4(09).

### Manuscripts (Under Review & In Preparation)

1. Chandra, D.\*, Altice, F., Copenhaver, M., DiDomizio, L.\*, & **Shrestha, R.** (2021, Revision submitted). Purposeful Fentanyl Use and Associated Factors among Opioid-Dependent People who Inject Drugs. *Substance Use and Misuse*.
2. Xhou, X.\*, Copenhaver, M., Altice, F., & **Shrestha, R.** (2021, Revision submitted). Trust in healthcare providers and the use of daily oral PrEP and willingness to use LAI-PrEP among opioid-dependent individuals: Examining the moderating role of race/ethnicity. *AIDS & Behavior*.
3. Mistler, C.\*, **Shrestha, R.**, Gunstad, J., Sanborn, V., & Copenhaver, M. (2021, Revision submitted). Adapting Intervention approaches for patients with opioid use disorder to accommodate their cognitive dysfunction. *General Psychiatry*.

4. Kim, R.\*, Wickersham, J., Azwa, I., Galka, J., & **Shrestha, R.** (2021, *AIDS & Behavior*). Willingness to Use HIV Self-Testing (HIVST) for HIV prevention among Female Sex Workers in Malaysia.
5. Mistler, C.\*, Sullivan, M., Copenhaver, M., Meyer, J.P., Roth, A.M., Shenoi, S.V., Edelman, J.E., Wickersham, J., & **Shrestha, R.** (2020, Under review). Differential impacts of COVID-19 among racial-ethnic minorities with opioid use disorder. *Journal of Substance Abuse Treatment*.
6. Gunstad, J., Sanborn, V., **Shrestha, R.**, Mistler, C.\*, & Copenhaver, M. (2020, Under review). Cluster Analysis of Data from the Brief Inventory of Neurocognitive Impairment (BINI) to Develop Neuro-Cognitive Profiles Among Opioid-Dependent Patients in Drug Treatment. *Substance Abuse*.
7. Mistler, C.\*, Sullivan, M., Wickersham, J., Copenhaver, M., & **Shrestha, R.** (2020, Under review). Clinical and demographic correlates of willingness to use at-home testing measures for COVID-19 among opioid-dependent individuals. *Substance Abuse*.
8. Sullivan, M.\*, Mistler, C.\*, Copenhaver, M., Wickersham, J., Ni, Z., Kim, R., & **Shrestha, R.** (2020, Under review). Racial differences in willingness to vaccinate against COVID-19 in people with opioid use disorder. *Human Vaccines and Immunotherapeutics*.
9. Teti, M., Robinson, E., Landes, D.S., **Shrestha, R.** & Pichon, L.C. (2020, Under review). “Who? What? Is that a test?” African Americans in non-metropolitan Midwestern US identify knowledge gaps and opportunities for PrEP for HIV prevention. *Journal of Community Health*.
10. Kim, L.\*, Azwa, I., **Shrestha, R.**, Xiang, N.G., Lim, W.C., Kamarulzaman, A., & Wickersham, J. (2020, In Preparation). Drivers of HIV viral suppression among recently diagnosed HIV+ men who have sex with men in Kuala Lumpur, Malaysia.
11. Pederson, C.J., Wickersham, J., Khoshnood, K., Gibson, B.A., Kamarulzaman, A., Altice, F.L., & **Shrestha, R.** (2020, In Preparation). Prevalence and Correlates of Active Amphetamine-type Stimulants (ATS) Use Among Female Sex Workers in Malaysia.
12. DiDomizio, L.\*, Copenhaver, M., Altice, F., Wickersham, J., & **Shrestha, R.** (2020, In Preparation). Correlates of non-fatal overdose among opioid-dependent people who inject drugs.
13. Wickersham, J.A., Morozova, O., Azwa, I., **Shrestha, R.**, Lim, H.S., Gibson, B. (2020, In Preparation). Drivers of active syphilis infection in cisgender and transgender women sex workers in Malaysia.

14. DiDomizio, L.\*, **Shrestha, R.**, Galka, J., & Wickersham, J. (2020, In Preparation). Correlates of Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV prevention among Female Sex Workers in Malaysia.
15. Huedo-Medina, T., **Shrestha, R.**, Altice, F., Mistler, C.\*, & Copenhaver, M. (2020, In Preparation). A randomized controlled trial of the Holistic Health for HIV (3H+) intervention among high-risk HIV-infected opioid-dependent drug users.
16. Ni, Z.\*, **Shrestha, R.**, Altice, F., & Wickersham, J.A. (2020, In Preparation). Evaluating Physicians' Intention to Discriminate Against Men Who Have Sex with Men in Malaysia.
17. Wickersham, J.A., Lim, H.S., Akbar, M., McStea, **Shrestha, R.**, M., Lim, J., Kamarulzaman, A., & Altice, F.L. (2020, In Preparation). Concurrency between condomless anal sex and amphetamine use in men who have sex with men.
18. Ahmad, A.\*, **Shrestha, R.**, Wickersham, J.A., Kamarulzaman, A., & Altice, F.L. (2020, In Preparation). Impact of methadone dose on linkage to community-based methadone maintenance treatment post release.
19. Lim, H.S., Alias, H., Wong, L. P., Wickersham, J., & **Shrestha, R.** (2020, In Preparation). A Study of Willingness to Use HIV Self-Testing (HIVST) among Men Who Have Sex with Men and Transgender Women in Malaysia.
20. Deng, Y., **Shrestha, R.**, Altice, F., & Copenhaver, M. (2020, In Preparation). Estimation of cost-effectiveness of secondary HIV prevention intervention (Holistic Health for HIV) for HIV-infected opioid-dependent drug users in the United States.
21. Bachireddy, C., **Shrestha, R.**, Azbel, L., Kurmanalieva, A., Shumskaia, N., Rozanova, J., Wegman, M., Meyer, J.M., & Altice, F.L. (2020, In Preparation). Methadone Maintenance Therapy Uptake, Retention, and Linkage for People who Inject Drugs Transitioning from Prison to the Community in Kyrgyzstan: Evaluation of a National Program.

## **CONFERENCE PAPERS**

### **Oral Presentations**

1. Kim, R.\*, Wickersham, J., & **Shrestha, R.** (2021). Willingness to use HIV Self-Testing Among Female Sex Workers in Malaysia. *Oral presentation at the 42<sup>nd</sup> Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.
2. Mistler, C.\*, Sullivan, M., Copenhaver, M., Meyer, J.P., Roth, A.M., Sheno, S.V., Edelman, J.E., Wickersham, J., & **Shrestha, R.** (2021). Differential impacts of COVID-19 among racial-ethnic minorities with opioid use disorder. *Oral presentation at the 42<sup>nd</sup> Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.

3. Mistler, C.\*, Chandra, D., Copenhaver, M., Wickersham, J., & **Shrestha, R.** (2021). Engagement in harm reduction strategies after suspected fentanyl contamination among opioid-dependent individuals. *Oral presentation at the 42<sup>nd</sup> Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Virtual Meeting.
4. **Shrestha, R.**, DiDomizio, E., Kim, R., Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and willingness to use long-acting injectable PrEP (LAIP) among people who inject drugs. *Oral presentation at the 148th American Public Health Association (APHA) Conference*. Virtual Meeting.
5. Rankin, R.\*, Akbar, M., Azwa, I., Li, M., Lo, Y.R., **Shrestha, R.**, Wickersham, J.A. (2020). Is risk compensation real? The effect of perceived level of HIV transmission risk on risk behavior in an open-label pilot PrEP-based intervention in men who have sex with men in Malaysia. *Oral presentation at the Asia-Pacific AIDS & Co-Infections Conference*. Bangkok, Thailand.
6. Chandra, D., Altice, F., Copenhaver, M., DiDomizio, E., Zhou, X., & **Shrestha, R.** (2020). Intentional fentanyl drug use and associated factors among opioid-dependent people who inject drugs (PWID). *Oral presentation at the 148th American Public Health Association (APHA) Conference*. Virtual Meeting.
7. **Shrestha, R.**, DiDomizio, L., Kim, R., Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. *Oral presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD)*. Hollywood, Florida.
8. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Preliminary Evidence for Feasibility and Acceptability of an mHealth-Based Strategy to Improve Adherence to Pre-Exposure Prophylaxis (PrEP) among Drug Users. *Accepted for oral presentation at the 2019 National HIV Prevention Conference (NHPC)*. Georgia, USA.
9. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). HIV-Related Stigma, Motivation to Adhere to Medication, and ART Adherence among HIV-Positive Methadone-Maintained Patient. *Oral presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Washington, DC, USA.
10. **Shrestha, R.** & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Drug Users in Treatment. *Roundtable presentation at the 146th American Public Health Association (APHA) Conference*. San Diego, California.
11. **Shrestha, R.**, Altice, F., Karki, P., & Copenhaver, M. (2018). Integrated biobehavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs. *Oral presentation at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. New Orleans, Louisiana.

12. **Shrestha, R.,** & Copenhaver, M. (2018). Experiences Using Pre-Exposure Prophylaxis for HIV Prevention among High-Risk Drug Users. *Oral presentation at the 39th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. New Orleans, Louisiana.
13. **Shrestha, R.,** Altice, F., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2017). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. *Oral presentation at the 145th American Public Health Association (APHA) Conference*. Atlanta, Georgia.
14. **Shrestha, R.,** Altice, F., Karki, P., & Copenhaver, M. (2017). Developing an Integrated, Brief Bio-Behavioral HIV Prevention Intervention for High-Risk Drug Users in Treatment: Taking into Account the Impact of Neurocognitive Impairment. *Oral presentation at the 145th American Public Health Association (APHA) Conference*. Atlanta, Georgia.
15. **Shrestha, R.,** Karki, P., Altice, F., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis (PrEP) among high-risk drug users in treatment. *Oral presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. San Diego, California.
16. **Shrestha, R.,** Karki, P., Altice, F., & Copenhaver, M. (2017). Feasibility, Acceptability, and Preliminary Efficacy of an Integrated Bio-Behavioral Approach for Adherence to Pre-Exposure Prophylaxis (PrEP) and HIV Risk Reduction among High-Risk Drug Users. *Oral presentation at the University of Connecticut Graduate Student Research Forum*. Storrs, Connecticut.
17. **Shrestha, R.,** Karki, P., Copenhaver, M., & Altice, F. (2016). Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. *Oral presentation at the 2016 Connecticut Public Health Association Annual Conference*. New Haven, Connecticut.
18. **Shrestha, R.,** Huedo-Medina, T., Karki, P., & Copenhaver, M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
19. **Shrestha, R.,** Weikum, D., Copenhaver, M., & Altice, F. (2016). Influence of Neurocognitive Impairment, Depression, and Alcohol Use Disorders on Quality of Life among Incarcerated, HIV-Positive Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
20. **Shrestha, R.,** Copenhaver, M., & Altice, F. (2016). A moderated mediating model of stigma, depression, and social support on quality of life among incarcerated, HIV-

- positive men with opioid dependence in Malaysia. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
21. Karki, P., **Shrestha, R.**, & Copenhaver, M. (2016). The Use of Female Sex Workers among Men in Nepal: Prevalence, STIs/HIV-Related Risk Behaviors, and Gender Ideology. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
  22. Ahmed, T., **Shrestha, R.**, Huedo-Medina, T., & Copenhaver, M. (2016). Self-efficacy mediates the effect of neurocognitive impairment on HIV risk reduction intervention outcomes among high-risk drug users in treatment. *Oral presentation at the 144th American Public Health Association (APHA) Conference*. Denver, Colorado.
  23. **Shrestha, R.**, & Copenhaver, M. (2015). Association between Intimate Partner Violence and STI/HIV-Related Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Oral presentation at the 143rd American Public Health Association (APHA) Conference*. Chicago, IL.
  24. **Shrestha, R.**, Karki, P., & Copenhaver, M. (2015). Early Sexual Debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. *Oral presentation at the 3rd International Conference on HIV/AIDS, STDs & STIs*. Atlanta, GA.
  25. **Shrestha, R.**, & Copenhaver, M. (2014). Association between Intimate Partner Violence against Women and HIV Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Oral presentation at the 2014 CHOP Global Health Conference*. Philadelphia, PA.
  26. **Shrestha, R.**, & Copenhaver, M. (2013). HIV-Related Risk Behaviors among Returnee Male Migrant Workers in Nepal. *Oral presentation at the 141st American Public Health Association (APHA) Conference*. Boston, MA.

### Poster Presentations

1. Pajarillo, C., Azwa, I., Akbar, M., Li, M., Lo, Y.R., **Shrestha, R.**, Wickersham, J.A. (2020). Occurrence of sexually transmitted infections in men who have sex with men receiving pre-exposure prophylaxis (PrEP) for HIV prevention: Results from Malaysia's first PrEP demonstration study. *Poster presentation at the Asia-Pacific AIDS & Co-Infections Conference*. Bangkok, Thailand.
2. **Shrestha, R.**, DiDomizio, L., Kim, R., Altice, F., Wickersham, J., & Copenhaver, M. (2020). Awareness about and interest in long-acting injectable pre-exposure prophylaxis (LAIP) use in people who use drugs. *Poster presentation at the 12th International Women's and Children's Health and Gender (InWomen's) Group conference*. Hollywood, Florida.

3. Mistler, C., Copenhaver, M., & **Shrestha, R.** (2020). The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: A systematic review. *Poster presentation at the 148th American Public Health Association (APHA) Conference*. Virtual Meeting.
4. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). HIV Testing Practices and Reasons for Never-Testing among Men Who Have Sex with Men (MSM) in Malaysia. *Poster presentation at the 10th IAS Conference on HIV Science (IAS 2019)*. Mexico City, Mexico.
5. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Preferences for long-acting injectable (LAI) versus daily oral pre-exposure prophylaxis (PrEP) among high-risk drug users. *Poster presentation at the 147th American Public Health Association (APHA) Conference*. Philadelphia, Pennsylvania.
6. **Shrestha, R.**, Ahmad, A., & Altice, F. (2019). Impact of Methadone Dose on Post-Release Linkage to Treatment among Incarcerated HIV-Infected Individuals Transitioning to the Community in Malaysia. *Poster presentation at the 147th American Public Health Association (APHA) Conference*. Philadelphia, Pennsylvania.
7. Ranjit, Y., **Shrestha, R.**, Copenhaver, M., & Altice, F. (2019). Online Information Seeking and Pre-Exposure Prophylaxis awareness among Drug Users Without HIV. *Poster presentation at the National Communication Association (NCA) 105th Annual Convention*. Baltimore, Maryland.
8. Teti, M., Robinson, E., Landes, D., Pichon, L., & **Shrestha, R.** (2019). “Who? What? Is that a test?” African Americans in non-metropolitan Midwestern US identify knowledge gaps and opportunities for PrEP for HIV prevention. *Poster presentation at the 147th American Public Health Association (APHA) Conference*. Philadelphia, Pennsylvania.
9. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Antiretroviral Therapy (ART) Adherence among HIV-Infected Opioid-Dependent Patients: The Role of HIV-Related Stigma and Motivation to Adhere to ART. *Poster presentation at the 2019 National HIV Prevention Conference (NHPC)*. Georgia, USA.
10. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Use of Smartphone to Find Sexual Health Information Online Among Malaysian MSM: Implications for mHealth Intervention. *Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Washington, DC, USA.
11. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Feasibility and Acceptability of an mHealth-Based Strategy to Improve Adherence to Pre-Exposure Prophylaxis among Drug Users. *Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. Washington, DC, USA.
12. **Shrestha, R.**, Ni, Z., Copenhaver, M., Altice, F., & Lim, S. (2019). HIV testing practices and reasons for never-testing among men who have sex with men (MSM) in Malaysia.

- Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD). San Antonio, TX.*
13. **Shrestha, R.**, Altice, F., Ssenyonjo, J., Sibilio, B., & Copenhaver, M. (2019). Testing an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among methadone-maintained patients: The CHRP-BB study. *Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD). San Antonio, TX.*
  14. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2019). Opioid-Dependent Women in Violent Relationship Are More Likely to Show Sub-Optimal Adherence to Pre-Exposure Prophylaxis (PrEP): Implications for Primary HIV Prevention. *Poster presentation at the 11th International Women's and Children's Health and Gender (InWomen's) Group Conference. San Antonio, TX.*
  15. Ssenyonjo, J., **Shrestha, R.**, & Copenhaver, M. (2019). Stigma May Influence Willingness and Uptake of Pre-Exposure Prophylaxis (PrEP) in High-risk Populations. *Accepted for poster presentation at the 40th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine. Washington, DC, USA.*
  16. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2018). HIV-Related Stigma, Motivation to Adhere to Antiretroviral Therapy, and Medication Adherence among HIV-Positive Methadone-Maintained Patients. *Poster presentation at the 9th International Conference on Stigma. Washington, DC, USA.*
  17. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2018). HIV-related stigma, motivation to adhere to ART, and ART adherence among HIV-infected methadone-maintained patients. *Poster presentation at the HIV Drug Therapy Glasgow 2018. Glasgow, UK.*
  18. **Shrestha, R.** & Copenhaver, M. (2018). Viral Suppression among HIV+ Methadone-Maintained Patients: The Role of Ongoing Injection Drug Use and Adherence to Antiretroviral Therapy. *Poster presentation at the 20th Annual International Meeting of the Institute of Human Virology. Baltimore, MD.*
  19. **Shrestha, R.** & Copenhaver, M. (2018). HIV Risk, and Awareness and Willingness to Use Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Female Drug Users. *Poster presentation at the Ending Gender Inequalities: Evidence to Impact Conference. Johannesburg, South Africa.*
  20. **Shrestha, R.** & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Female Drug Users in Treatment. *Poster presentation at the Ending Gender Inequalities: Evidence to Impact Conference. Johannesburg, South Africa.*
  21. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2018). Serostatus Non-Disclosure to Sexual Partners among High-Risk Drug Users Living with HIV: Examining the Roles of HIV-

- Related Stigma and Risk Behavior. *Poster presentation at the 22nd International AIDS Conference*. Amsterdam, Netherlands.
22. Bachireddy, C., **Shrestha, R.**, Azbel, L., Kurmanalieva, A., Shumskaia, N., Rozanova, J., Meyer, J.P., & Altice, F. (2018). Methadone maintenance therapy uptake, retention, and linkage for people who inject drugs transitioning from prison to the community in Kyrgyzstan: Evaluation of a national program. *Poster presentation at the 22nd International AIDS Conference*. Amsterdam, Netherlands.
  23. **Shrestha, R.** & Copenhaver, M. (2018). Exploring the Use of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among High-Risk Drug Users in Treatment. *Poster presentation at the 22nd International AIDS Conference (AIDS 2018)*. Amsterdam, Netherlands.
  24. **Shrestha, R.** & Copenhaver, M. (2018). Perceived HIV Risk Mediates the Relationship Between HIV Risk Behavior & Willingness to Use Pre-Exposure Prophylaxis among Drug Users. *Poster presentation at the Annual Conference of the College on Problems of Drug Dependence (CPDD)*. San Diego, CA.
  25. Ssenyonjo, J., **Shrestha, R.**, & Copenhaver, M. (2018). Stigma May Influence Willingness and Uptake of Pre-Exposure Prophylaxis (PrEP) Among High-risk Populations. *Poster presentation at the University of Connecticut Graduate Student Research Forum*. Storrs, Connecticut.
  26. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. (2017). Using conjoint analysis to measure the Acceptability of pre-exposure prophylaxis (PrEP) use for HIV prevention among high-risk drug users in treatment. *Poster presentation at the 9th IAS Conference on HIV Science*. Paris, France.
  27. **Shrestha, R.**, Altice, F., Huedo-Medina, T., Karki, P., & Copenhaver, M. (2017). Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment. *Poster presentation at the 9th IAS Conference on HIV Science*. Paris, France.
  28. **Shrestha, R.**, Altice, F., Karki, P., Huedo-Medina, T., & Copenhaver, M. (2017). Feasibility, Acceptability, and preliminary efficacy of the Bio-Behavioral Community-friendly Health Recovery Program (CHRP-BB): A combination approach for primary HIV prevention among high-risk drug users. *Poster presentation at the 9th IAS Conference on HIV Science*. Paris, France.
  29. **Shrestha, R.**, Altice, F., & Copenhaver, M. (2017). Examining the Acceptability of mHealth Technology in HIV Prevention among High-risk Drug Users in Treatment. *Poster presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. San Diego, California.

30. **Shrestha, R.**, Karki, P., Altice, F., & Copenhaver, M. (2017). Developing a Bio-Behavioral HIV Intervention for High-Risk Drug Users: Taking into Account the Impact of Neurocognitive Impairment. *Poster presentation at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine*. San Diego, California.
31. Karki, P., **Shrestha, R.**, Altice, F., Huedo-Medina, T., & Copenhaver, M. (2017). Correlates of willingness to use Pre-Exposure Prophylaxis (PrEP) among high-risk drug users in treatment. *Poster presentation at the University of Connecticut Graduate Student Research Forum*. Storrs, Connecticut.
32. **Shrestha, R.**, Karki, P., Copenhaver, M., & Altice, F. (2016). The Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. *Poster presentation at the HIV Drug Therapy Glasgow*. Glasgow, UK.
33. **Shrestha, R.**, Karki, P., Huedo-Medina, T., & Copenhaver, M. (2016). The Moderating Role of Treatment Engagement on the Relationship between Neurocognitive Impairment and Antiretroviral Treatment (ART) Adherence. *Poster presentation at the 18<sup>th</sup> International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV*. New York, NY.
34. **Shrestha, R.**, Huedo-Medina, T., Karki, P., & Copenhaver, M. (2016). Modeling a Theory-Based Approach to Examine the Influence of Neurocognitive Impairment on HIV Risk Reduction Behaviors among Drug Users. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. Palm Springs, California.
35. **Shrestha, R.**, Karki, P., & Copenhaver, M. (2016). An Exploratory Factor Analysis of a Brief Self-Report Scale to Detect Neurocognitive Impairment Among Participants Enrolled in Methadone Maintenance Therapy. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. Palm Springs, California.
36. **Shrestha, R.**, & Copenhaver, M. (2016). Association between Intimate Partner Violence and STI/HIV-Related Risk Behaviors: Findings from the Nepal Demographic Health Survey. *Poster presentation at the Ending Gender Inequalities: Addressing the Nexus of HIV, Drug Use, and Violence with Evidence-based Action conference*. Chapel Hill, NC.
37. **Shrestha, R.**, Huedo-Medina, T., & Copenhaver, M. (2015). Sex-Related Differences in Self-Reported Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Treatment Program. *Poster presentation at the 143rd American Public Health Association (APHA) Conference*. Chicago, IL.
38. **Shrestha, R.**, & Copenhaver, M. (2015). Gender Differences in Associations between Neurocognitive Impairment and Cocaine Use among High-Risk Cocaine-Dependent

- Methadone-Maintained Patients. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. Phoenix, Arizona.
39. **Shrestha, R.**, & Copenhaver, M. (2014). Early Sexual Debut: A Risk Factor for STIs/HIV Acquisition among a Nationally Representative Sample of Adults in Nepal. *Poster presentation at the 2015 Connecticut Public Health Association (CPHA) Annual Conference*. Waterbury, CT.
  40. **Shrestha, R.**, & Copenhaver, M. (2014). Developing an Evidence-Based Intervention Targeting High-Risk Migrant Workers. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. San Juan, Puerto Rico.
  41. **Shrestha, R.**, & Copenhaver, M. (2014). Gender-Related Differences in Neurocognitive Impairment among High-Risk Cocaine Users in Methadone Maintenance Program. *Poster presentation at the 2014 Connecticut Public Health Association (CPHA) Annual Conference*. Waterbury, CT.
  42. **Shrestha, R.**, & Copenhaver, M. (2013). HIV Risk Behaviors among Returnee Male Migrant Workers in Nepal. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. San Diego, CA.
  43. Copenhaver, M., Altice, F., & **Shrestha, R.** (2013). Using a Non-Inferiority Trial Approach to Test the Holistic Health for HIV (3H+) Intervention among HIV+ Drug Users. *Poster presentation at the annual conference of the College on Problems of Drug Dependence (CPDD)*. San Diego, CA.
  44. **Shrestha, R.**, Huedo-Medina, T., & Copenhaver, M. (2013). HIV-Related Risk Behaviors among Migrant and Non-Migrant Workers in Nepal. *Poster presentation delivered at the Health, Workplace, and Environment: Cultivating Connections Conference*. Storrs, Connecticut.
  45. **Shrestha, R.**, & Copenhaver, M. (2013). Understanding HIV-Risk Behaviors among Returnee Male Migrant Workers in Nepal. *Poster presentation at the 2013 Connecticut Public Health Association (CPHA) Annual Conference*. Waterbury, CT.
  46. **Shrestha, R.**, & Joshi, J. (2011). Characterizing Staurosporine Induced Cell Death in Various Cell Lines. *Poster presentation at the North East Alliance (NEA) Summer Research Program*. Storrs, Connecticut.
  47. **Shrestha, R.**, & Joshi, J. (2010). Mechanistic Differences of Silica and Staurosporine Induced Death in MH-S Alveolar Macrophages and HeLa Cells. *Poster presentation at the North East Alliance (NEA) Summer Research Program*. Storrs, Connecticut.

### Invited Talks/Presentations

1. **Shrestha, R.** (2020). Mobile Technologies for HIV Prevention: Using mHealth to Enhance PrEP Care Continuum among MSM in Malaysia. ID/Rheum Research Conference. Yale University.
2. **Shrestha, R.** (2020). Guest speaker (for Dr. Copenhaver, AHS). mHealth for HIV prevention among key populations in Malaysia. University of Connecticut.
3. **Shrestha, R.** (2019). mHealth-Based Approach: A Potential Platform to Enhance PrEP Care Continuum among Malaysian MSM. Yale Clinical and Community Research Seminar Series. Yale University.
4. **Shrestha, R.** (2019). Guest speaker (for Dr. Copenhaver, AHS). Mobile Technologies for HIV Prevention: Using mHealth to Enhance PrEP Care Continuum among MSM in Malaysia. University of Connecticut.
5. **Shrestha, R.** (2018). Developing and Testing a Brief, Integrated Bio-Behavioral HIV Prevention Intervention for High-Risk Drug Users. CIRA Clinical and Health Services Research Core Meeting. Yale University.
6. **Shrestha, R.** (2018). Exploring the use of pre-exposure prophylaxis for HIV prevention among high-risk drug users in treatment. Yale Clinical and Community Research Seminar Series. Yale University.
7. **Shrestha, R.** (2018). Guest speaker (for Dr. Copenhaver, AHS). Integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and reduce HIV risk in people who use drugs. University of Connecticut.
8. **Shrestha, R.** (2017). Guest speaker (for Dr. Copenhaver, AHS). Developing & Testing a Bio-Behavioral HIV Prevention Intervention for High-Risk Drug Users. University of Connecticut
9. **Shrestha, R.** (2016). Influence of Neurocognitive Impairment, Depression, & Alcohol Use Disorders on Quality of Life among Incarcerated, HIV+ Opioid Dependent Malaysian Men: A Moderated Mediation Analysis. Yale Clinical and Community Research Seminar Series. Yale University.
10. **Shrestha, R.** (2016). Guest speaker (for Dr. Copenhaver, AHS). HIV-Risk Reduction Intervention and Neurocognitive Impairment. University of Connecticut.
11. **Shrestha, R.** (2015). Guest speaker (for Dr. Copenhaver, AHS). The Influence of Neurocognitive Impairment on HIV Risk Reduction Intervention Outcomes. University of Connecticut.
12. **Shrestha, R., & Clark, I.** (2012). National Committee for Quality Assurance Patient-Centered Medical Home Accreditation of United Communities and Family Services

Edward and Mary Lord Family Health Center. Community Health Center Association of Connecticut Meeting. Connecticut.

## **TEACHING EXPERIENCE**

Spring 2017 **Teaching Assistant**, Biostatistics for Health Professions (Undergraduate-level course, 3 Credits)  
Department of Allied Health Sciences, University of Connecticut

Fall 2016 **Teaching Assistant**, Critical Issues in Health Promotion, Disease, & Disability Prevention (Graduate-level course, 3 Credits)  
Department of Allied Health Sciences, University of Connecticut

Spring 2016 **Instructor**, Writing Allied Health Research (Graduate-level course, 1 Credit)  
Department of Allied Health Sciences, University of Connecticut

**Teaching Assistant**, Research for the Health Professionals (Graduate-level course, 3 Credits)  
Department of Allied Health Sciences, University of Connecticut

Fall 2015 **Instructor**, Writing Allied Health Research (Graduate-level course, 1 Credit)  
Department of Allied Health Sciences, University of Connecticut

**Teaching Assistant**, Research for the Health Professionals (Graduate-level course, 3 Credits)  
Department of Allied Health Sciences, University of Connecticut

Spring 2015 **Teaching Assistant**, Health Education & Behavioral Interventions for At-risk Populations (Graduate-level course, 3 Credits)  
Department of Allied Health Sciences, University of Connecticut

## **TEACHING/MENTORSHIP DEVELOPMENT**

*Rayne Kim, Postgraduate Associate, Yale University*

*Philip Tamburrino, Postgraduate Associate, Yale University*

*Colleen Mistler, PhD student, UConn [Primary mentor: Michael Copenhaver]*

*Jude Ssenyonjo, PhD student, UConn [Primary mentor: Michael Copenhaver]*

*Zhao Ni, Post-doc, Yale University [Primary mentor: Frederick Altice]*

*Libby Didomizio, Postgraduate Associate, Yale University [Primary mentor: Frederick Altice]*

*Divya Chandra, Postgraduate Associate, Yale University [Primary mentor: Frederick Altice]*

## **PRESS COVERAGE**

1. ContagionLive (July 12<sup>th</sup>, 2019): Trial Pairs PrEP with Behavioral Intervention to Prevent HIV in Drug Users.

2. Infectious Disease Advisor (July 9<sup>th</sup>, 2018): Reduced HIV Viral Suppression Among Methadone-Maintained Patients.
3. AIDSFree Prevention Update (June 6<sup>th</sup>, 2016): Behavioral Prevention.